Drug repositioning for cancer therapy based on large-scale drug-induced transcriptional signatures

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Lee, Haeseung ^a   Kang, Seungmin ^a   Kim, Wankyu ^a  

^a Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTINEOPLASTIC AGENT; APOMORPHINE; ASTEMIZOLE; IVERMECTIN; MAPROTILINE; MOMETASONE FUROATE; NORTRIPTYLINE; TRIFLURIDINE; TRANSCRIPTOME;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BURKITT LYMPHOMA; CANCER THERAPY; CELL VIABILITY; COLON CANCER; COLORECTAL CANCER; COMPUTER MODEL; DRUG APPROVAL; DRUG INDICATION; DRUG REPOSITIONING; DRUG STRUCTURE; DRUG TARGETING; FEMALE; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA; HUMAN; HUMAN CELL; LUNG CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; MELANOMA; MENINGIOMA; ONCOGENE; OVARY CANCER; PROSTATE CANCER; SQUAMOUS CELL CARCINOMA; BIOLOGY; CELL SURVIVAL; CLUSTER ANALYSIS; COMPUTER SIMULATION; DRUG EFFECTS; DRUG SCREENING; FACTUAL DATABASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SCREENING; INFORMATION PROCESSING; METABOLISM; NEOPLASMS; PROCEDURES; REPRODUCIBILITY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, FACTUAL; DATASETS AS TOPIC; DRUG REPOSITIONING; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84961149614     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150460     Document Type: Article

References (70)

1. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3: 673-83. doi: 10.1038/nrd1468 PMID: 15286734
2. Ekins S, Williams AJ, Krasowski MD, Freundlich JS. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today. Elsevier Ltd; 2011; 16: 298-310. doi: 10.1016/j.drudis. 2011.02.016
3. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther. 2013; 93: 335-41. doi: 10.1038/clpt.2013.1 PMID: 23443757
4. Lussier Y a, Chen JL. The emergence of genome-based drug repositioning. Sci Transl Med. 2011; 3: 96ps35. doi: 10.1126/scitranslmed.3001512 PMID: 21849663
5. Liu Z, Fang H, Reagan K, Xu X, Mendrick DL, Slikker W, et al. In silico drug repositioning: what we need to know. Drug Discov Today. Elsevier Ltd; 2013; 18: 110-5. doi: 10.1016/j.drudis.2012.08.005
6. Ma D-L, Chan DS-H, Leung C-H. Drug repositioning by structure-based virtual screening. Chem Soc Rev. 2013; 42: 2130-41. doi: 10.1039/c2cs35357a PMID: 23288298
7. Chen B, Wild D, Guha R. PubChem as a source of polypharmacology. J Chem Inf Model. 2009; 49: 2044-55. doi: 10.1021/ci9001876 PMID: 19708682
8. García-Sosa A, Oja M. DrugLogit: logistic discrimination between drugs and nondrugs including disease-specificity by assigning probabilities based on molecular properties. J Chem Inf Model. 2012; n/ a-n/a. doi: 10.1021/ci200587h
9. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, et al. DrugBank 3.0: a comprehensive resource for "omics" research on drugs. Nucleic Acids Res. Oxford University Press; 2011; 39: D1035-D1041. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3013709&tool= pmcentrez&rendertype=abstract. doi: 10.1093/nar/gkq1126 PMID: 21059682
10. Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008; 321: 263-6. doi: 10.1126/science.1158140 PMID: 18621671
11. Ye H, Liu Q, Wei J. Construction of drug network based on side effects and its application for drug repositioning. PLoS One. Public Library of Science; 2014; 9: e87864. Available: http://journals.plos.org/ plosone/article?id=10.1371/journal.pone.0087864. doi: 10.1371/journal.pone.0087864 PMID: 24505324
12. Yang L, Agarwal P. Systematic drug repositioning based on clinical side-effects. Csermely P, editor. PLoS One. Public Library of Science; 2011; 6: e28025. doi: 10.1371/journal.pone.0028025 PMID: 22205936
13. Wang Y, Chen S, Deng N, Wang Y. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and phenotype data. PLoS One. Public Library of Science; 2013; 8: e78518. Available: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078518. doi: 10.1371/ journal.pone.0078518 PMID: 24244318
14. Iwata H, Sawada R, Mizutani S, Yamanishi Y. Systematic Drug Repositioning for a Wide Range of Diseases with Integrative Analyses of Phenotypic and Molecular Data. J Chem Inf Model. 2015; 55: 446-459. doi: 10.1021/ci500670q PMID: 25602292
15. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol. 2012; 8: e1002503. doi: 10.1371/journal.pcbi. 1002503 PMID: 22589709
16. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using geneexpression signatures to connect small molecules, genes, and disease. Science. 2006; 313: 1929-35. doi: 10.1126/science.1132939 PMID: 17008526
17. Iorio F, Isacchi A, di Bernardo D, Brunetti-Pierri N. Discovery of drug mode of action and drug repositioning from transcriptional responses. PNAS. 2010; 6: 1204-5. doi: 10.1073/pnas.1000138107
18. Hu G, Agarwal P. Human disease-drug network based on genomic expression profiles. PLoS One. 2009; 4: e6536. doi: 10.1371/journal.pone.0006536 PMID: 19657382
19. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan A a, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011; 3: 96ra77. doi: 10.1126/scitranslmed.3001318 PMID: 21849665
20. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011; 3: 96ra76. doi: 10.1126/scitranslmed.3002648 PMID: 21849664
21. Iskar M, Zeller G, Blattmann P, Campillos M, Kuhn M, Kaminska KH, et al. Characterization of druginduced transcriptional modules: towards drug repositioning and functional understanding. Mol Syst Biol. EMBO and Macmillan Publishers Limited; 2013; 9: 662. doi: 10.1038/msb.2013.20 PMID: 23632384
22. Wang K, Sun J, Zhou S, Wan C, Qin S, Li C, et al. Prediction of Drug-Target Interactions for Drug Repositioning Only Based on Genomic Expression Similarity. Markel S, editor. PLoS Comput Biol. Public Library of Science; 2013; 9: e1003315. Available: http://dx.plos.org/10.1371/journal.pcbi.1003315. doi: 10.1371/journal.pcbi.1003315 PMID: 24244130
23. Gottlieb A, Stein GY, Ruppin E, Sharan R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol. Nature Publishing Group; 2011; 7: 496. doi: 10.1038/msb.2011.26
24. Iorio F, Shrestha RL, Levin N, Boilot V, Garnett MJ, Saez-Rodriguez J, et al. A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions. PLoS One. 2015; 10: e0139446. doi: 10.1371/journal.pone.0139446 PMID: 26452147
25. Shin E, Lee YC, Kim SR, Kim SH, Park J. Drug Signature-based Finding of Additional Clinical Use of LC28-0126 for Neutrophilic Bronchial Asthma. Sci Rep. Nature Publishing Group; 2015; 5: 17784. doi: 10.1038/srep17784 PMID: 26626943
26. Vidovic D, Koleti A, Schürer SC. Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action. Front Genet. 2014; 5: 342. doi: 10.3389/fgene.2014. 00342 PMID: 25324859
27. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature. 2009; 462: 175-81. doi: 10.1038/nature08506 PMID: 19881490
28. Kumar V, Krishna S, Siddiqi MI. Virtual screening strategies: Recent advances in the identification and design of anti-cancer agents. Methods. Elsevier Inc.; 2015; 71: 64-70. doi: 10.1016/j.ymeth.2014.08. 010
29. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, et al. DrugBank 3.0: a comprehensive resource for "omics" research on drugs. Nucleic Acids Res. Oxford University Press; 2011; 39: D1035-D1041. doi: 10.1093/nar/gkq1126 PMID: 21059682
30. Davis AP, Murphy CG, Johnson R, Lay JM, Lennon-Hopkins K, Saraceni-Richards C, et al. The Comparative Toxicogenomics Database: update 2013. Nucleic Acids Res. 2013; 41: D1104-14. doi: 10.1093/nar/gks994 PMID: 23093600
31. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of largescale molecular data sets. Nucleic Acids Res. 2012; 40: D109-14. doi: 10.1093/nar/gkr988 PMID: 22080510
32. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2013; 1-7. doi: 10.1093/nar/gkt1068 PMID: 24203711
33. Günther S, Kuhn M, Dunkel M, Campillos M, Senger C, Petsalaki E, et al. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res. 2008; 36: D919-22. doi: 10.1093/ nar/gkm862 PMID: 17942422
34. Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012; 40: D1128-36. Available: http:// www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3245130&tool=pmcentrez&rendertype=abstract. doi: 10.1093/nar/gkr797 PMID: 21948793
35. Roth BL, Lopez E, Patel S, Kroeze WK. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? Neurosci. 2000; 6: 252-262. doi: 10.1177/ 107385840000600408
36. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007; 35: D198-201. Available: http:// www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1751547&tool=pmcentrez&rendertype=abstract. PMID: 17145705
37. Bento a P, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2014; 42: D1083-90. doi: 10.1093/nar/gkt1031 PMID: 24214965
38. Olah M, Rad R, Ostopovici L, Bora A, Hadaruga N, Hadaruga D, et al. WOMBAT and WOMBAT-PK: Bioactivity Databases for Lead and Drug Discovery [Internet]. Schreiber SL, Kapoor TM, Wess G, editors. Weinheim, Germany: Wiley-VCH Verlag GmbH; 2007. doi: 10.1002/9783527619375
39. Liu Y, Wei Q, Yu G, Gai W, Li Y, Chen X. DCDB 2.0: a major update of the drug combination database. Database (Oxford). 2014; 2014: bau124. Available: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=4275564&tool=pmcentrez&rendertype=abstract.
40. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets - update. Nucleic Acids Res. 2013; 41: D991-5. Available: http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=3531084&tool=pmcentrez&rendertype=abstract. doi: 10.1093/nar/gks1193 PMID: 23193258
41. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98: 5116-21. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=33173&tool=pmcentrez&rendertype=abstract. PMID: 11309499
42. Peck D, Crawford ED, Ross KN, Stegmaier K, Golub TR, Lamb J. A method for high-throughput gene expression signature analysis. Genome Biol. 2006; 7: R61. Available: http://genomebiology.com/2006/ 7/7/R61. PMID: 16859521
43. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011; 3: 33. Available: http://www.jcheminf.com/content/3/1/33. doi: 10.1186/1758-2946-3-33 PMID: 21982300
44. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155: 462-77. doi: 10.1016/j.cell.2013.09.034 PMID: 24120142
45. Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker BA, Suzek TO, et al. An overview of the PubChem BioAssay resource. Nucleic Acids Res. Oxford University Press; 2010; 38: D255-D266. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2808922&tool= pmcentrez&rendertype=abstract. doi: 10.1093/nar/gkp965 PMID: 19933261
46. Meir EG Van, Hadjipanayis CG, Norden AD, Shu H, Wen PY, Olson JJ. Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. 2010; 60: 166-193. doi: 10.3322/caac. 20069.Exciting PMID: 20445000
47. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. United States; 2005; 352: 987-996. doi: 10.1056/NEJMoa043330 PMID: 15758009
48. Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits ED. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med. 1984; 311: 549-52. doi: 10.1056/NEJM198408303110901 PMID: 6379459
49. Melotti A, Mas C, Kuciak M, Lorente-trigos A, Borges I. The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. 2014; 6: 1263-1278.
50. Hashimoto H, Messerli SM, Sudo T, Maruta H. Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther. 2009; 3: 243-6. Available: http://www.ncbi.nlm.nih.gov/pubmed/22495656. PMID: 22495656
51. RESULTS / DISCUSSION. Our results indicate that TFT can indeed cross the BBB and that it can be detected in brain, along with its metabolites, as early as 15 minutes post-injection. Four major resonances were identified in the spectra of brain extract. 1988; 14: 60201.
52. Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014; 2319-2326. doi: 10.3892/or.2014.3487 PMID: 25230742
53. Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, MacCioni RB. Selective interaction of lansoprazole and Astemizole with tau polymers: Potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimer's Dis. 2010; 19: 573-589. doi: 10.3233/JAD-2010-1262
54. Huang X, Dubuc AM, Hashizume R, Berg J, He Y, Wang J, et al. Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev. 2012; 26: 1780-1796. doi: 10.1101/gad.193789.112 PMID: 22855790
55. Jangi SM, Díaz-Pérez JL, Ochoa-Lizarralde B, Martín-Ruiz I, Asumendi A, Pérez-Yarza G, et al. H1 histamine receptor antagonists induce genotoxic and caspase-2-dependent apoptosis in human melanoma cells. Carcinogenesis. 2006; 27: 1787-1796. doi: 10.1093/carcin/bgl021 PMID: 16569656
56. Huang BS, Leenen FHH. Sympathoinhibitory and depressor effects of amlodipine in spontaneously hypertensive rats. J Cardiovasc Pharmacol. United States; 2003; 42: 153-160. PMID: 12883316
57. Yoshida J, Ishibashi T, Nishio M. G1 cell cycle arrest by amlodipine, a dihydropyridine Ca2+ channel blocker, in human epidermoid carcinoma A431 cells. Biochem Pharmacol. England; 2007; 73: 943-953. doi: 10.1016/j.bcp.2006.12.011 PMID: 17217918
58. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res. 1992; 52: 2413-2418. PMID: 1533173
59. Cloonan SM, Drozgowska A, Fayne D, Williams DC. The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leuk Lymphoma. England; 2010; 51: 523-539. doi: 10.3109/ 10428190903552112 PMID: 20141432
60. Hsu S-S, Chen W-C, Lo Y-K, Cheng J-S, Yeh J-H, Cheng H-H, et al. Effect of the antidepressant maprotiline on Ca2+ movement and proliferation in human prostate cancer cells. Clin Exp Pharmacol Physiol. Australia; 2004; 31: 444-449. doi: 10.1111/j.1440-1681.2004.04024.x
61. Neef C, Laar T Van. Relationships of Apomorphine in Patients with Parkinson ' s Disease. Clin Pharmacokinet. 1999; 37: 257-271. PMID: 10511920
62. Lissoni P, Malugani F, Manganini V, Ardizzoia A, Gardani G, Bartolacelli E, et al. Psychooncology and cancer progression-related alterations advanced cancer patients. 2003; 24.
63. Ejsing TB, Linnet K. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier. Hum Psychopharmacol. 2005; 20: 149-153. doi: 10.1002/hup.667 PMID: 15624117
64. Pilkington GJ, Akinwunmi J, Amar S. The role of tricyclic drugs in selective triggering of mitochondriallymediated apoptosis in neoplastic glia : a therapeutic option in malignant glioma ? Radiol Oncol. 2006; 40: 73-85.
65. Parker KA, Glaysher S, Hurren J, Knight LA, McCormick D, Suovouri A, et al. The effect of tricyclic antidepressants on cutaneous melanoma cell lines and primary cell cultures. Anticancer Drugs. 2012; 23: 65-9. Available: http://www.ncbi.nlm.nih.gov/pubmed/21897201. doi: 10.1097/CAD. 0b013e32834b1894 PMID: 21897201
66. Abdou HS, Villeneuve G, Tremblay JJ. The calcium signaling pathway regulates leydig cell steroidogenesis through a transcriptional cascade involving the nuclear receptor NR4A1 and the steroidogenic acute regulatory protein. Endocrinology. 2013; 154: 511-20. Available: http://www.ncbi.nlm.nih.gov/ pubmed/23183170. doi: 10.1210/en.2012-1767 PMID: 23183170
67. Jan C-R, Su J-A, Teng C-C, Sheu M-L, Lin P-Y, Chi M-C, et al. Mechanism of maprotiline-induced apoptosis: role of [Ca2+](i), ERK, JNK and caspase-3 signaling pathways. Toxicology. 2013; 304: 1-12. Available: http://www.ncbi.nlm.nih.gov/pubmed/23219590. doi: 10.1016/j.tox.2012.11.013 PMID: 23219590
68. Ohba T, Watanabe H, Murakami M, Radovanovic M, Iino K, Ishida M, et al. Amlodipine inhibits cell proliferation via PKD1-related pathway. Biochem Biophys Res Commun. 2008; 369: 376-81. Available: http://www.ncbi.nlm.nih.gov/pubmed/18298949. doi: 10.1016/j.bbrc.2008.02.075 PMID: 18298949
69. Boland ML, Chourasia AH, Macleod KF. Mitochondrial dysfunction in cancer. Front Oncol. 2013; 3: 292. doi: 10.3389/fonc.2013.00292 PMID: 24350057
70. Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol. 2014; 10: 305-12. doi: 10.1038/nchembio.1471 PMID: 24584101